PT-141 (Bremelanotide) Research Guide

Full name: Bremelanotide (PT-141 / Vyleesi)

A synthetic melanocortin peptide FDA-approved for HSDD in premenopausal women. Works through CNS to enhance sexual desire rather than vascular mechanisms.

How PT-141 (Bremelanotide) Works

MC4R agonist in hypothalamus activating central sexual arousal pathways. Increases dopaminergic signaling independent of vascular mechanisms.

Dosing Protocol

• Typical dose: 1.75 mg
• Frequency: As needed, ~45 min before activity
• Duration: As needed
• Route: Subcutaneous injection

Reported Benefits

• Increased sexual desire
• Central arousal mechanism
• Works both sexes (research)
• Non-vascular
• Rapid onset

Potential Side Effects

• Nausea (40%)
• Flushing
• Headache
• Transient hypertension
• Skin darkening (rare)

Research Citations

1. RECONNECT trials: Bremelanotide for HSDD (2019) - Significantly increased sexual desire and reduced distress vs placebo, leading to FDA approval.
2. MC4R activation in male sexual dysfunction (2021) - Produced erections in 80% of men who failed PDE5 inhibitors via central mechanisms.

Related Sexual Health Compounds

• Kisspeptin-10 - Full Profile
• Melanotan II - Full Profile
• Oxytocin - Full Profile
• Tadalafil Peptide - Full Profile
• TriMix - Full Profile
• Tadalafil - Full Profile

View full PT-141 (Bremelanotide) profile with 3D molecule viewer →